STOCK TITAN
  1. Home
  2. News
  3. IMMP

Immutep Limited - IMMP STOCK NEWS

Welcome to our dedicated news page for Immutep (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immutep's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immutep's position in the market.

News
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Rhea-AI Summary
Immutep announces positive preliminary topline results from Cohort B of the TACTI-003 Phase IIb trial, showing a 26.9% response rate in first-line head and neck squamous cell carcinoma patients who do not express PD-L1. The investigational combination of eftilagimod alpha and KEYTRUDA® demonstrates promising overall response and disease control rates, expanding treatment options for this challenging cancer type. The data suggests that efti's unique activation of antigen-presenting cells enhances the immune system's response to anti-PD-(L)1 therapies, potentially benefiting patients with negative PD-L1 expression. The study continues to collect and analyze data, with full results expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
clinical trial
-
News
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Rhea-AI Summary
Immutep partners with CHDR for a Phase I trial of IMP761, a LAG-3 agonist antibody to treat autoimmune diseases. The trial will utilize a unique challenge model to assess pharmacological activity. IMP761 aims to restore immune system balance and target autoimmune disease causes. The study is set to begin in mid-CY2024 with 49 healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
management clinical trial
-
News
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Rhea-AI Summary
Immutep receives positive feedback from the Spanish Medicines Agency for the upcoming TACTI-004 registrational trial in metastatic non-small cell lung cancer. The AEMPS supports Immutep moving into a registrational trial in 1L NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Rhea-AI Summary
Immutep Limited announces positive safety and initial efficacy data from the AIPAC-003 trial, showing encouraging results in metastatic breast cancer patients. The combination of 90mg efti with paclitaxel is safe and well-tolerated, with a 50% overall response rate and a 100% disease control rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.06%
Tags
clinical trial
-
News
Immutep Quarterly Activities Report Q2 FY24
Rhea-AI Summary
Immutep Limited (IMMP) reports promising clinical data from various phase II and III trials, including strong overall survival and response rates in non-small cell lung cancer patients. The company is well-financed with a cash balance of A$103.7 million, providing cash runway to early CY 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Rhea-AI Summary
Immutep Limited (IMM) Announces Enrollment of First Patient in INSIGHT-005 Phase I Trial for Urothelial Carcinoma Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
none
News
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces constructive feedback from the Paul-Ehrlich-Institut regarding the planned TACTI-004 Phase III trial of eftilagimod alpha for first line treatment of metastatic non-small cell lung cancer. The PEI is supportive of Immutep moving into a registrational trial in first line NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy. Immutep plans to announce its final trial design for TACTI-004 in Q1 of CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The company also received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program. The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
News
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Rhea-AI Summary
Immutep Limited (IMM) announces the expansion of the INSIGHT-003 trial to four sites in Germany, supporting faster enrolment in the study evaluating eftilagimod alpha in combination with KEYTRUDA and doublet chemotherapy for NSCLC. The trial is expected to complete recruitment in 1H CY2024, with promising early clinical data showing a 70.6% overall response rate and 10.9-month median progression-free survival in patients with PD-L1 TPS of <50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
clinical trial
News
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the completion of patient enrollment in the TACTI-003 Phase IIb trial evaluating efti in combination with pembrolizumab for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The trial enrolled 171 patients in the US, Europe, and Australia, with the primary endpoint being Overall Response Rate. Results are expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
clinical trial
Stock IMMP logo
Immutep Limited

Nasdaq:IMMP

IMMP Rankings

#3379 Ranked by Market Cap
#1726 Ranked by Stock Gains
N/A Ranked by Dividends

IMMP Stock Data

296.02M
1.06B
0.01%
2.77%
1.06%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Sydney

About IMMP

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.